[{"data":1,"prerenderedAt":150},["ShallowReactive",2],{"compound-cjc-1295-ipamorelin":3,"compound-related-cjc-1295-ipamorelin":129,"compound-reading-cjc-1295-ipamorelin":141},{"id":4,"title":5,"alsoKnownAs":6,"body":7,"casNumber":100,"category":101,"description":92,"extension":102,"faq":103,"meta":110,"molecularFormula":100,"molecularWeight":100,"name":111,"navigation":112,"path":113,"presentations":114,"purity":117,"rank":118,"relatedCompounds":119,"relatedResearch":122,"seo":125,"sequence":100,"stem":126,"summary":127,"__hash__":128},"compounds\u002Fcompounds\u002Fcjc-1295-ipamorelin.md","CJC-1295 & Ipamorelin Blend","GH axis blend",{"type":8,"value":9,"toc":91},"minimark",[10,15,19,23,26,33,39,48,51,55,58,61,69,73,76,84,88],[11,12,14],"h2",{"id":13},"what-this-is","What this is",[16,17,18],"p",{},"A single vial containing Modified GRF (1-29) — CJC-1295 without DAC — and\nipamorelin, lyophilised together in a fixed ratio. Both compounds sit in growth\nhormone axis research, act on different receptors, and appear together often\nenough that a combined preparation saves a reconstitution step.",[11,20,22],{"id":21},"why-the-pairing-is-interesting","Why the pairing is interesting",[16,24,25],{},"The two compounds engage the axis at different points through different\nreceptors.",[16,27,28,32],{},[29,30,31],"strong",{},"CJC-1295"," is an analogue of growth hormone-releasing hormone and acts at the\nGHRH receptor — the physiological \"release\" signal, coupled to cAMP.",[16,34,35,38],{},[29,36,37],{},"Ipamorelin"," acts at GHS-R1a, the ghrelin receptor, through a distinct\nsignalling pathway.",[16,40,41,42,47],{},"Because the receptors are separate and the pathways do not overlap, co-activation\nis studied as a way of engaging two independent inputs to the same axis rather\nthan saturating one. The GHRH analogue in this blend is the non-DAC form, which\nproduces a short pulse rather than the sustained receptor occupancy of the DAC\nversion — a distinction that matters in any design where pulsatility is a\nvariable. See the ",[43,44,46],"a",{"href":45},"\u002Fcompounds\u002Fcjc-1295","CJC-1295 page"," for that difference in\nfull.",[16,49,50],{},"Supplied for in-vitro laboratory research only. No therapeutic claim is made and\nno dosing or administration guidance is provided.",[11,52,54],{"id":53},"analytical-notes","Analytical notes",[16,56,57],{},"A blend is two materials in one vial, and it needs two sets of results.",[16,59,60],{},"Each component is synthesised and analysed separately before blending — its own\nHPLC purity figure, its own mass spectrometry identity confirmation — and both\nappear on the batch certificate. The masses here are conveniently far apart\n(~3,368 Da and ~712 Da), so a single mass spectrum resolves both components\ncleanly, and a certificate reporting only one observed mass for a two-component\nblend has answered half the question.",[16,62,63,64,68],{},"The chromatography is similarly unambiguous: a 29-residue peptide and a\n5-residue peptide are well separated on a reversed-phase column, so the two main\npeaks should be plainly distinct. If a blend's certificate shows a single peak,\nsomething is wrong with the document or with the vial. See\n",[43,65,67],{"href":66},"\u002Fresearch\u002Fspotting-a-fabricated-coa","spotting a fabricated COA",".",[11,70,72],{"id":71},"handling-and-storage","Handling and storage",[16,74,75],{},"Store sealed at −20 °C, protected from light and moisture. Bring to room\ntemperature before opening, add diluent down the vial wall, and swirl rather than\nshake. Store solution at 2–8 °C, protected from light.",[16,77,78,79,83],{},"Reconstituting a blend gives two concentrations from one volume — each\ncomponent's mass divided by the diluent volume. Run the\n",[43,80,82],{"href":81},"\u002Ftools\u002Freconstitution-calculator","reconstitution calculator"," once per component.",[11,85,87],{"id":86},"what-we-supply","What we supply",[16,89,90],{},"Both components released against a ≥99% purity specification individually, with\nper-component HPLC and mass spectrometry results and the mass of each component\nrecorded on a single batch-specific Certificate of Analysis. Select batches\nadditionally receive independent third-party purity verification.",{"title":92,"searchDepth":93,"depth":93,"links":94},"",2,[95,96,97,98,99],{"id":13,"depth":93,"text":14},{"id":21,"depth":93,"text":22},{"id":53,"depth":93,"text":54},{"id":71,"depth":93,"text":72},{"id":86,"depth":93,"text":87},null,"Blends","md",[104,107],{"question":105,"answer":106},"Why are these two compounds paired?","They act on different receptors within the same regulatory axis. CJC-1295 is a GHRH receptor agonist; ipamorelin is a growth hormone secretagogue receptor agonist. Because the receptors and their signalling pathways are distinct, co-activation is studied as a way of engaging the axis at two points rather than pushing harder at one.",{"question":108,"answer":109},"What should a blend certificate show?","Two purity figures and two mass confirmations — one per component — plus the mass of each component in the vial. A single combined purity percentage is not a meaningful result for a two-component blend, because the chromatogram has two main peaks and one number cannot describe both.",{},"CJC-1295 + Ipamorelin",true,"\u002Fcompounds\u002Fcjc-1295-ipamorelin",[115,116],"2 mg + 2 mg vial","5 mg + 5 mg vial","≥99% per component",22,[120,121],"cjc-1295","ipamorelin",[123,124],"how-to-read-a-peptide-coa","mass-spectrometry-peptide-identity",{"title":5,"description":92},"compounds\u002Fcjc-1295-ipamorelin","A combined preparation of Modified GRF (1-29) and ipamorelin, pairing a GHRH receptor agonist with a selective ghrelin receptor agonist.","Xtl76rwHRJhu4IK8U71Fccgr6KfoHvazjhQ9xu4L188",[130,136],{"path":45,"name":31,"alsoKnownAs":131,"summary":132,"category":133,"molecularWeight":134,"purity":135},"Modified GRF (1-29) · CJC-1295 without DAC","A modified growth hormone-releasing hormone analogue, engineered for resistance to enzymatic cleavage while retaining a short pulsatile signal.","Growth Hormone","~3,368 Da","≥99%",{"path":137,"name":37,"alsoKnownAs":138,"summary":139,"category":133,"molecularWeight":140,"purity":135},"\u002Fcompounds\u002Fipamorelin","NNC 26-0161","A selective growth hormone secretagogue receptor agonist, notable for acting on the ghrelin receptor without the appetite and cortisol effects of earlier secretagogues.","~711.9 Da",[142,146],{"path":143,"title":144,"description":145},"\u002Fresearch\u002Fhow-to-read-a-peptide-coa","How to Read a Peptide Certificate of Analysis","A field-by-field walkthrough of a peptide COA — what each number establishes, which fields are load-bearing, and what a missing batch number tells you about the rest of the document.",{"path":147,"title":148,"description":149},"\u002Fresearch\u002Fmass-spectrometry-peptide-identity","What Mass Spectrometry Establishes That HPLC Cannot","Purity and identity are different questions requiring different instruments. Why a chromatogram alone cannot tell you which peptide is in the vial, and what a mass spectrum on a COA should actually show.",1787473952615]